Central Alabama Research LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$11,527	5
2024	Research	$281,349	20
2023	Research	$891,767	47
2022	Research	$602,442	30
2021	Research	$12,123	1
2020	Research	$6,100	2
2019	Research	$266,820	9

Breakdown

Who paid Research payments · program years 2019–2025

Bavarian Nordic A/S $1,340,659 76 payments
Genentech, Inc. $458,550 27 payments
Pfizer Inc. $257,448 5 payments
Regeneron Pharmaceuticals, Inc. $15,472 6 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $738,217 46 payments
Nct05238025 $602,442 30 payments
Transmission Study Household $447,023 22 payments
A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $204,474 3 payments
A Phase 3 Randomized Double Blind Placebo and Activecontrolled Multicenter Parallelgroup Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain $52,054 1 payment
CT-388-104 OW/OB with T2D $11,527 5 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk $6,372 3 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia Or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk $6,100 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-To-Severe Chronic Low Back Pain and Osteoarthritis of the Hip Or Knee $3,000 1 payment
A Phase 3 Multicenter Longterm Observational Study of Subjects From Tanezumab Studies Who Undergo A Total Knee Hip Or Shoulder Replacement $920 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.